Hims Daily (Jul 17, 2025)

Jul 17, 2025

🚨 First Hims Data Tracker of Q3 drops TOMORROW… Upgrade to paid for access.

Stock slid -3.5% on muted volume — After multiple failed attempts to clear $52, sellers broke the $50 floor this afternoon before we bounced (barely) into the close.
- Just 50% of average volume trading hands - 20M shares overall
Still no ZAVA 8-K — Hims announced the ZAVA acquisition as closed on July 9 in its Canada expansion press release, but the required 8-K has yet to be filed. With the 4-business-day deadline now passed, many investors are confused as to why there is still no 8-K.
Street tone remains constructive, but cautious — Truist bumped its target to $48 (from $45) but kept its Hold rating. The move came as part of a broader healthcare tech update in which Truist highlighted the sector’s relative insulation from tariffs
VP of AI hire stirs culture debate — Yesterday, Hims announced Shankar Sadasivam, ex-Cruise and ex-Qualcomm, as its Vice President of AI. Some see it as another sharp addition to its increasingly stacked leadership team. Others are uneasy about it being the second major hire from Cruise, a company viewed by some in the Valley as a cautionary tale of overhyped tech and internal dysfunction.
60% of subscribers are now on personalized plans — Dr. Primack said the shift away from one-sized-fits-all approaches is officially the norm at Hims, and called tailored care “a medical necessity.” It marks a key step in Hims’ evolution toward more durable, individualized offerings